Photo: Courtesy of Celgene (https://www.celgene.com/media-library/celgene-logo-with-tagline-no-background/)

28 September 2015Americas

USPTO rejects Celgene bid for Bass sanctions

The US Patent and Trademark Office (USPTO) has rejected a request by biopharmaceutical company Celgene to sanction hedge fund manager Kyle Bass and his organisation the Coalition for Affordable Drugs.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

IPR of pre-AIA patents isn’t unconstitutional, finds Fed Circuit

31 July 2019 In a defeat for biotech company Celgene, the US Court of Appeals for the Federal Circuit has concluded that the retroactive application of inter partes review proceedings to a pre-American Invents Act patent isn’t unconstitutional.

Americas

PTAB grants IPR of Celgene patents after Kyle Bass challenge

28 October 2015 The Coalition for Affordable Drugs, an organisation closely tied to hedge fund manager Kyle Bass, has persuaded the Patent Trial and Appeal Board to institute an inter partes review concerning the validity of two patents owned by biopharmaceutical company Celgene.

Americas

Profit is at the heart of every IPR, says Kyle Bass

13 August 2015 Hedge fund manager Kyle Bass has fired a response to a motion filed by biotechnology company Celgene seeking to sanction him over “abusive” patent challenges, stating that profit motive is at the centre of every inter partes review filing.